Is CLDX or CLYM more profitable?

Climb Bio's return on equity of -31.79% beat Celldex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Celldex Therapeutics N/A -52.35% -47.61% Climb Bio N/A -31.79% -30.79%

Does the media favor CLDX or CLYM?

In the previous week, Celldex Therapeutics and Celldex Therapeutics both had 6 articles in the media. Climb Bio's average media sentiment score of 0.47 beat Celldex Therapeutics' score of 0.04 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Climb Bio 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NRIX or CLYM?

In the previous week, Climb Bio had 2 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Climb Bio and 4 mentions for Nurix Therapeutics. Climb Bio's average media sentiment score of 0.47 beat Nurix Therapeutics' score of 0.12 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Climb Bio 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMNM or CLYM more profitable?

Climb Bio's return on equity of -31.79% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -50.56% -46.93% Climb Bio N/A -31.79% -30.79%

Does the media favor IMNM or CLYM?

In the previous week, Immunome had 3 more articles in the media than Climb Bio. MarketBeat recorded 9 mentions for Immunome and 6 mentions for Climb Bio. Immunome's average media sentiment score of 0.61 beat Climb Bio's score of 0.47 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, SLS or CLYM?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SELLAS Life Sciences Group N/A N/A -$26.86M -$0.21 N/A Climb Bio N/A N/A -$59.85M -$0.83 N/A

Is SLS or CLYM more profitable?

Climb Bio's return on equity of -31.79% beat SELLAS Life Sciences Group's return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -35.91% -33.34% Climb Bio N/A -31.79% -30.79%

Does the media prefer SLS or CLYM?

In the previous week, Climb Bio had 5 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Climb Bio and 1 mentions for SELLAS Life Sciences Group. Climb Bio's average media sentiment score of 0.47 beat SELLAS Life Sciences Group's score of 0.25 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Climb Bio 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RXRX or CLYM?

In the previous week, Recursion Pharmaceuticals had 7 more articles in the media than Climb Bio. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 6 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.47 beat Recursion Pharmaceuticals' score of 0.27 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Climb Bio 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Climb Bio (CLYM) Competitors

$10.86 +0.15 (+1.40%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$11.10 +0.24 (+2.25%)

As of 09:20 AM Eastern

Compare

CLYM vs. CLDX, NRIX, IMNM, SLS, and RXRX

Should you buy Climb Bio stock or one of its competitors? Climb Bio's main competitors and comparable companies include Celldex Therapeutics (CLDX), Nurix Therapeutics (NRIX), Immunome (IMNM), SELLAS Life Sciences Group (SLS), and Recursion Pharmaceuticals (RXRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Climb Bio compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Celldex Therapeutics currently has a consensus price target of $61.92, suggesting a potential upside of 111.34%. Climb Bio has a consensus price target of $27.62, suggesting a potential upside of 154.29%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Celldex Therapeutics and Celldex Therapeutics both had 6 articles in the media. Climb Bio's average media sentiment score of 0.47 beat Celldex Therapeutics' score of 0.04 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Climb Bio	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

69.8% of Climb Bio shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Climb Bio has lower revenue, but higher earnings than Celldex Therapeutics. Climb Bio is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,494.11	-$258.76M	-$4.35	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Celldex Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Climb Bio has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

Climb Bio's return on equity of -31.79% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
Climb Bio	N/A	-31.79%	-30.79%

Summary

Climb Bio beats Celldex Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Climb Bio compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Nurix Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market. Comparatively, Climb Bio has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Nurix Therapeutics presently has a consensus target price of $34.21, suggesting a potential upside of 54.05%. Climb Bio has a consensus target price of $27.62, suggesting a potential upside of 154.29%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Climb Bio has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Climb Bio's return on equity of -31.79% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Climb Bio	N/A	-31.79%	-30.79%

69.8% of Climb Bio shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Climb Bio has lower revenue, but higher earnings than Nurix Therapeutics. Climb Bio is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	27.45	-$264.46M	-$3.45	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

In the previous week, Climb Bio had 2 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Climb Bio and 4 mentions for Nurix Therapeutics. Climb Bio's average media sentiment score of 0.47 beat Nurix Therapeutics' score of 0.12 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Climb Bio beats Nurix Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Climb Bio compare to Immunome?

Immunome (NASDAQ:IMNM) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Immunome currently has a consensus price target of $34.25, indicating a potential upside of 77.37%. Climb Bio has a consensus price target of $27.62, indicating a potential upside of 154.29%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Immunome has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market. Comparatively, Climb Bio has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

Climb Bio's return on equity of -31.79% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Climb Bio	N/A	-31.79%	-30.79%

44.6% of Immunome shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Immunome had 3 more articles in the media than Climb Bio. MarketBeat recorded 9 mentions for Immunome and 6 mentions for Climb Bio. Immunome's average media sentiment score of 0.61 beat Climb Bio's score of 0.47 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Climb Bio has lower revenue, but higher earnings than Immunome. Climb Bio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	316.03	-$212.39M	-$2.53	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Summary

Climb Bio beats Immunome on 8 of the 14 factors compared between the two stocks.

How does Climb Bio compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

SELLAS Life Sciences Group has a beta of 2.56, meaning that its stock price is 156% more volatile than the broader market. Comparatively, Climb Bio has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

In the previous week, Climb Bio had 5 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Climb Bio and 1 mentions for SELLAS Life Sciences Group. Climb Bio's average media sentiment score of 0.47 beat SELLAS Life Sciences Group's score of 0.25 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SELLAS Life Sciences Group currently has a consensus price target of $10.00, suggesting a potential downside of 11.19%. Climb Bio has a consensus price target of $27.62, suggesting a potential upside of 154.29%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Climb Bio's return on equity of -31.79% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Climb Bio	N/A	-31.79%	-30.79%

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Summary

Climb Bio beats SELLAS Life Sciences Group on 11 of the 14 factors compared between the two stocks.

How does Climb Bio compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Recursion Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Climb Bio has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market.

Climb Bio has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Climb Bio's return on equity of -31.79% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
Climb Bio	N/A	-31.79%	-30.79%

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Recursion Pharmaceuticals had 7 more articles in the media than Climb Bio. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 6 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.47 beat Recursion Pharmaceuticals' score of 0.27 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Climb Bio has lower revenue, but higher earnings than Recursion Pharmaceuticals. Climb Bio is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	28.32	-$644.76M	-$1.04	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Recursion Pharmaceuticals currently has a consensus price target of $8.06, indicating a potential upside of 104.05%. Climb Bio has a consensus price target of $27.62, indicating a potential upside of 154.29%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Climb Bio beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Climb Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLYM vs. The Competition

Export

Metric	Climb Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$615.14M	$3.87B	$7.19B	$13.31B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-13.08	13.89	274.66	26.04
Price / Sales	N/A	1,168.65	579.54	80.85
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	3.23	16.47	10.95	6.27
Net Income	-$59.85M	-$22.69M	$3.50B	$382.01M
7 Day Performance	-0.73%	-2.85%	-1.82%	-1.60%
1 Month Performance	-27.84%	-11.14%	-6.33%	-4.63%
1 Year Performance	474.60%	8.31%	3.09%	-0.95%

Climb Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLYM Climb Bio	2.6285 of 5 stars	$10.86 +1.4%	$27.62 +154.3%	+503.3%	$615.14M	N/A	N/A	29
CLDX Celldex Therapeutics	2.1783 of 5 stars	$31.65 -1.6%	$61.92 +95.6%	+7.6%	$2.49B	$1.54M	N/A	198	High Trading Volume
NRIX Nurix Therapeutics	2.2144 of 5 stars	$22.99 -1.5%	$34.21 +48.8%	+122.5%	$2.39B	$83.98M	N/A	357
IMNM Immunome	2.8338 of 5 stars	$20.90 +0.0%	$34.25 +63.9%	+37.8%	$2.37B	$6.94M	N/A	177
SLS SELLAS Life Sciences Group	0.4203 of 5 stars	$11.74 +3.6%	$10.00 -14.8%	+483.4%	$2.37B	N/A	N/A	13

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLYM) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Climb Bio (CLYM) Competitors

CLYM vs. CLDX, NRIX, IMNM, SLS, and RXRX

How does Climb Bio compare to Celldex Therapeutics?

Summary

How does Climb Bio compare to Nurix Therapeutics?

Summary

How does Climb Bio compare to Immunome?

Summary

How does Climb Bio compare to SELLAS Life Sciences Group?

Summary

How does Climb Bio compare to Recursion Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Climb Bio (CLYM) Competitors

CLYM vs. CLDX, NRIX, IMNM, SLS, and RXRX

How does Climb Bio compare to Celldex Therapeutics?

Do analysts recommend CLDX or CLYM?

Does the media favor CLDX or CLYM?

Do institutionals & insiders hold more shares of CLDX or CLYM?

Which has preferable valuation and earnings, CLDX or CLYM?

Which has more risk and volatility, CLDX or CLYM?

Is CLDX or CLYM more profitable?

Summary

How does Climb Bio compare to Nurix Therapeutics?

Which has more volatility & risk, NRIX or CLYM?

Do analysts rate NRIX or CLYM?

Is NRIX or CLYM more profitable?

Do insiders & institutionals hold more shares of NRIX or CLYM?

Which has stronger valuation & earnings, NRIX or CLYM?

Does the media prefer NRIX or CLYM?

Summary

How does Climb Bio compare to Immunome?

Do analysts prefer IMNM or CLYM?

Which has more risk and volatility, IMNM or CLYM?

Is IMNM or CLYM more profitable?

Do insiders & institutionals believe in IMNM or CLYM?

Does the media favor IMNM or CLYM?

Which has stronger earnings and valuation, IMNM or CLYM?

Summary

How does Climb Bio compare to SELLAS Life Sciences Group?

Which has more risk and volatility, SLS or CLYM?

Does the media prefer SLS or CLYM?

Do analysts recommend SLS or CLYM?

Do insiders and institutionals have more ownership in SLS or CLYM?

Is SLS or CLYM more profitable?

Which has better earnings & valuation, SLS or CLYM?

Summary

How does Climb Bio compare to Recursion Pharmaceuticals?

Which has more risk & volatility, RXRX or CLYM?

Is RXRX or CLYM more profitable?

Do institutionals & insiders hold more shares of RXRX or CLYM?

Does the media favor RXRX or CLYM?

Which has higher earnings and valuation, RXRX or CLYM?

Do analysts rate RXRX or CLYM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools